HHS awarded SIGA Technologies $518M for R&D in Biotechnology, a sole-source contract

Contract Overview

Contract Amount: $518,482,778 ($518.5M)

Contractor: Siga Technologies, Inc.

Awarding Agency: Department of Health and Human Services

Start Date: 2011-05-13

End Date: 2023-12-31

Contract Duration: 4,615 days

Daily Burn Rate: $112.3K/day

Competition Type: NOT COMPETED

Number of Offers Received: 1

Pricing Type: FIRM FIXED PRICE

Sector: R&D

Official Description: DRUGS AND BIOLOGICALS

Place of Performance

Location: CORVALLIS, BENTON County, OREGON, 97333

State: Oregon Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $518.5 million to SIGA TECHNOLOGIES, INC. for work described as: DRUGS AND BIOLOGICALS Key points: 1. Contract value significantly exceeds initial estimates, raising questions about cost control. 2. Sole-source award limits competitive pressure, potentially inflating prices. 3. Long contract duration (over 12 years) suggests a sustained need but also potential for scope creep. 4. Fixed-price contract shifts some risk to the government if costs escalate. 5. The contract is for Research and Development in Biotechnology, a critical but complex sector. 6. Geographic location in Oregon may indicate specific R&D facilities or regional economic considerations.

Value Assessment

Rating: questionable

The total award of $518 million over more than 12 years represents a substantial investment. Benchmarking this against similar R&D contracts in biotechnology is challenging due to the specialized nature of the work and the sole-source award. However, the sheer scale of the funding for a single contractor warrants scrutiny regarding whether alternative, more competitive approaches could have yielded better value for taxpayer dollars. The fixed-price nature of the contract means the government bears the risk of cost overruns if the research proves more expensive than anticipated.

Cost Per Unit: N/A

Competition Analysis

Competition Level: sole-source

This contract was awarded on a sole-source basis, meaning it was not competed. This typically occurs when only one responsible source is available or in cases of urgent need. The lack of competition means there was no opportunity for other companies to bid, which can limit price discovery and potentially lead to higher costs for the government. The justification for a sole-source award in this instance would need to be thoroughly reviewed to ensure it was appropriate.

Taxpayer Impact: Sole-source awards mean taxpayers do not benefit from the cost savings that can arise from a competitive bidding process. This can result in a higher overall expenditure for the government.

Public Impact

The primary beneficiary is the Department of Health and Human Services (HHS), specifically the Office of Assistant Secretary for Preparedness and Response (ASPR), in its mission to prepare for and respond to public health emergencies. The contract supports research and development in biotechnology, likely focused on countermeasures against biological threats. The geographic impact is centered in Oregon, where SIGA Technologies is located, potentially supporting local jobs and the regional biotech ecosystem. Workforce implications include specialized scientific and technical roles within SIGA Technologies and potentially related research institutions.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Lack of competition raises concerns about potential overpayment and reduced innovation.
Long-term nature of the contract could lead to complacency or a lack of urgency.
The significant dollar amount awarded without competition requires strong justification and oversight.

Positive Signals

The contract addresses a critical area of national security and public health preparedness.
SIGA Technologies has a specific focus and expertise in the contracted R&D area.
The fixed-price contract provides some cost certainty for the government, assuming the scope is well-defined.

Sector Analysis

The biotechnology sector is characterized by high R&D investment, long development cycles, and significant regulatory hurdles. Contracts in this area often involve specialized scientific expertise and intellectual property considerations. The total federal spending on R&D in biotechnology is substantial, with agencies like HHS, NIH, and DOD being major funders. This contract represents a significant portion of spending directed towards a specific company within this niche, highlighting the importance of its work in preparedness.

Small Business Impact

This contract does not appear to involve small business set-asides, as SIGA Technologies is a public company. There is no explicit information regarding subcontracting plans for small businesses. The focus on a large, sole-source award to an established entity may limit opportunities for smaller firms to participate in this specific area of government contracting.

Oversight & Accountability

Oversight for this contract would primarily fall under the Department of Health and Human Services, likely through the Office of the Assistant Secretary for Preparedness and Response (ASPR). Transparency would depend on the public availability of contract modifications, performance reports, and any justification documents for the sole-source award. Inspector General oversight would be applicable to ensure proper use of funds and adherence to contract terms.

Related Government Programs

Biodefense Research and Development
Medical Countermeasures
Public Health Emergency Preparedness
Biotechnology Research Grants
National Biodefense Strategy

Risk Flags

Sole-source award lacks competitive justification.
High contract value without competition warrants scrutiny.
Long contract duration increases risk of cost escalation and scope creep.
Fixed-price contract shifts cost overrun risk to the government.

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $518.5 million to SIGA TECHNOLOGIES, INC.. DRUGS AND BIOLOGICALS

Who is the contractor on this award?

The obligated recipient is SIGA TECHNOLOGIES, INC..

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Office of Assistant Secretary for Preparedness and Response).

What is the total obligated amount?

The obligated amount is $518.5 million.

What is the period of performance?

Start: 2011-05-13. End: 2023-12-31.

What specific products or research outcomes has SIGA Technologies delivered under this contract, and how do they align with ASPR's preparedness goals?

The contract with SIGA Technologies, Inc. (Contract Number 75A50118C00027, though the provided data suggests an earlier award date and potentially a different identifier) is primarily for the development and procurement of smallpox antiviral drugs, specifically tecovirimat (TPOXX). ASPR's goal is to ensure the availability of medical countermeasures against public health threats, including bioterrorism agents like smallpox. SIGA's drug is intended to treat disease caused by viruses in the orthopoxvirus genus. Performance metrics would likely include successful completion of research phases, adherence to development timelines, and meeting efficacy and safety standards required for regulatory approval and stockpiling. The long duration and significant funding indicate a sustained effort towards achieving these preparedness objectives, though specific delivery milestones and their achievement would require deeper contract file analysis.

How does the $518 million total award compare to other federal investments in smallpox countermeasures or similar antiviral R&D?

The $518 million awarded to SIGA Technologies represents a substantial federal investment in a specific smallpox countermeasure. To benchmark this, one would need to compare it against the total federal spending on the Strategic National Stockpile (SNS) for antivirals, other contracts for smallpox therapeutics or vaccines, and broader R&D funding for emerging infectious diseases. For instance, other contracts might exist for different stages of development, manufacturing scale-up, or alternative countermeasures. The Biomedical Advanced Research and Development Authority (BARDA), within HHS, manages many such contracts. Without a comprehensive analysis of all related federal procurements and grants in this specific therapeutic area, it's difficult to definitively state if $518 million is high or low, but it indicates a significant commitment to SIGA's product line as a key component of national preparedness.

What is the justification for the sole-source award, and were there any attempts to explore competitive alternatives?

Sole-source awards are typically justified when only one responsible source can fulfill the requirement, often due to unique capabilities, proprietary technology, or urgent needs where competition is not feasible. For SIGA Technologies and its smallpox antiviral drug, the justification likely stems from the company holding patents or exclusive rights to the specific compound (tecovirimat) and having advanced it through significant prior development, potentially with prior federal investment. Agencies must document these justifications extensively. While the provided data states 'NOT COMPETED,' a full review of the contract file would reveal the specific justification cited by ASPR. It is possible that previous market research or early-stage development efforts by SIGA were deemed unique enough to preclude meaningful competition at the time of this award, but this requires verification.

What are the key risks associated with this long-term, sole-source contract, and what mitigation strategies are in place?

Key risks include potential cost overruns if research proves more complex than anticipated (though mitigated somewhat by fixed-price), lack of innovation due to absence of competitive pressure, and the possibility that the government becomes locked into a specific technology that may be superseded. Mitigation strategies often involve robust government oversight, clear performance metrics, regular reviews of the contract's necessity and pricing, and contingency planning for alternative solutions. For a sole-source contract, the government might negotiate specific clauses related to intellectual property, data rights, or price adjustments based on market changes. The long duration necessitates active contract management to ensure continued value and alignment with evolving public health needs.

How has federal spending on SIGA Technologies or similar antiviral R&D evolved over time, and what trends does this contract reflect?

Federal spending on SIGA Technologies, particularly related to tecovirimat, has likely evolved in phases, reflecting the drug's development lifecycle from initial research to procurement for the Strategic National Stockpile. This $518 million award suggests a significant commitment, possibly representing a transition from R&D funding to procurement or a large-scale R&D phase. Trends in federal spending on antiviral R&D are generally increasing, driven by concerns over emerging infectious diseases (like COVID-19), bioterrorism threats, and antimicrobial resistance. Contracts like this reflect a strategic focus on specific threats (smallpox) and a reliance on established, albeit sole-source, providers to meet critical national security and public health needs. Historical data would show if this represents a peak or a continuation of prior investment levels.

Industry Classification

NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in Biotechnology

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: NOT COMPETED

Solicitation Procedures: ONLY ONE SOURCE

Offers Received: 1

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 35 E 62ND ST, NEW YORK, NY, 10065

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $518,482,778

Exercised Options: $518,482,778

Current Obligation: $518,482,778

Actual Outlays: $1,377,134

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: YES

Timeline